Bull
$6.63
シナリオ価格
$4.850
+0.061 (+1.25%)終値時点
Nu Skin Enterprises, Inc. develops and distributes a comprehensive line of beauty and wellness solutions in approximately 50 markets worldwide. It has nine segments, consisting of its seven geographic Nu Skin segments - Americas, Southeast Asia/Pacific, Mainland China, Japan, Europe & Africa, South Korea, and Hong Kong/Taiwan - and two Rhyz segments - Manufacturing and Rhyz Other. Its beauty & skincare solutions include acne and blemishes, anti-aging, dark circles and puffiness, discoloration, dry skin, lines and wrinkles, and oily skin and pores. Its health & wellness solutions include gut health, bone and joint health, brain health, energy and stamina, heart health, immunity support, and protein and fitness. It offers various beauty devices, including ageLOC LumiSpa, Nu Skin RenuSpa iO and Prysm iO. Its ageLOC LumiSpa includes products such as LumiSpa iO Superpower Kit, ageLOC Rose Gold LumiSpa iO, LumiSpa Rose Gold Accent Twin Pack, and others.
NU Skin Enterprises Inc is currently not a strong buy. The stock is priced at 4.85, which is significantly lower than its 200-day simple moving average of 7.549, indicating a bearish trend. Additionally, the forward P/E ratio is 5.9032, suggesting it may be undervalued compared to its earnings potential, but the recent net income drop to -249798000 in Q2 2026 raises concerns about profitability. The RSI is at 52.765, indicating neutral momentum, and the stock has a year-to-date change of -49.95%, reflecting significant underperformance. The main risk is the negative net margin of -78.03% in Q2 2026, which indicates ongoing financial struggles.
DA Davidson
$7
2024-12-20
DA Davidson
2024-12-20
目標株価
$7
Citigroup
$6.75
2024-10-22
Citigroup
2024-10-22
目標株価
$6.75
DA Davidson
$11
2024-08-12
DA Davidson
2024-08-12
目標株価
$11
Citigroup
$12
2024-08-09
Citigroup
2024-08-09
目標株価
$12
DA Davidson
$13
2024-05-09
DA Davidson
2024-05-09
目標株価
$13
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

Analysis of Short Interest in Consumer Staples

Positive Outlook for Cosmetics Industry Amid Growth Trends

Nu Skin (NUS) Q1 2026 Earnings Transcript

Nu Skin Enterprises Q1 2026 Earnings Call Insights

Nu Skin Launches Prysm iO Intelligent Wellness Platform
Nu Skin Enterprises, Inc. develops and distributes a comprehensive line of beauty and wellness solutions in approximately 50 markets worldwide. It has nine segments, consisting of its seven geographic Nu Skin segments - Americas, Southeast Asia/Pacific, Mainland China, Japan, Europe & Africa, South Korea, and Hong Kong/Taiwan - and two Rhyz segments - Manufacturing and Rhyz Other. Its beauty & skincare solutions include acne and blemishes, anti-aging, dark circles and puffiness, discoloration, dry skin, lines and wrinkles, and oily skin and pores. Its health & wellness solutions include gut health, bone and joint health, brain health, energy and stamina, heart health, immunity support, and protein and fitness. It offers various beauty devices, including ageLOC LumiSpa, Nu Skin RenuSpa iO and Prysm iO. Its ageLOC LumiSpa includes products such as LumiSpa iO Superpower Kit, ageLOC Rose Gold LumiSpa iO, LumiSpa Rose Gold Accent Twin Pack, and others. It operates in the Consumer Non-Cyclicals sector (WHOLESALE-DRUGS, PROPRIETARIES & DRUGGISTS' SUNDRI industry).
NU Skin Enterprises Inc is currently not a strong buy. The stock is priced at 4.85, which is significantly lower than its 200-day simple moving average of 7.549, indicating a bearish trend. Additionally, the forward P/E ratio is 5.9032, suggesting it may be undervalued compared to its earnings potential, but the recent net income drop to -249798000 in Q2 2026 raises concerns about profitability. The RSI is at 52.765, indicating neutral momentum, and the stock has a year-to-date change of -49.95%, reflecting significant underperformance. The main risk is the negative net margin of -78.03% in Q2 2026, which indicates ongoing financial struggles.
6 analysts cover NUS: 3 rate it Buy, 1 Hold and 2 Sell.
本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。